Stocks · News reference

Coherus Oncology shares are trading higher after the company announced a special dividend of contingent value rights.

Aug 18, 2026, 2:40 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 17, 2026, 9:37 PMBenzinga Newsdesk
Coherus Oncology Reveals Special Dividend of Biosimilar Contingent Value Rights; Company Intends To Immediately Commence A Sale Process For The Legacy Biosim Assets
Coherus Oncology, Inc. (NASDAQ:CHRS) ("Coherus", "Coherus Oncology" or the "Company") today announced a special dividend of contingent value rights (each, a "CVR" and collectively, the
Read original at benzinga
CHRS
SEC EDGARAug 17, 2026, 9:28 PMSEC EDGAR
8-K filing — Coherus Oncology, Inc. (CHRS)
Filed: 2026-08-17 AccNo: 0001104659-26-097951 Size: 467 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar
CHRS
BenzingaAug 7, 2026, 5:08 PMBenzinga Newsdesk
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $12 to $10.
Read original at benzinga
CHRS